May 18, 2026The Lancet Microbe2 citationsOpen Access
Exceeding expectations: factors contributing to the potency of human papillomavirus vaccines
View Full Paper
Key Points
- This review aims to explore the factors that enhance the potency of HPV vaccines and their implications for future vaccine development.
- Analysis of the immunological and virological attributes of HPV vaccines.
- Examination of clinical trial efficacy and effectiveness in national immunization programs.
- Discussion of biological plausibility for long-term protection after a single dose.
- HPV vaccines provide high-level, long-term protection with a single priming dose.
- No booster doses are necessary to maintain effectiveness.
- High immunogenicity raises projections for eliminating vaccine-targeted types with sufficient adolescent coverage.
Abstract
The commercial prophylactic vaccines for human papillomavirus (HPV) are subunit vaccines composed of spontaneously assembled virus-like particles formed from 360 copies of the L1 major virion protein. The vaccines have exceeded expectations in immunogenicity, clinical trials efficacy, and effectiveness in national immunisation programmes. Booster doses are not required to generate these outcomes. In this Review, we discuss the immunological and virological considerations that can help with explaining the high potency of HPV vaccines. These considerations provide biological plausibility for HPV vaccines being the first subunit vaccines to confer high-level, long-term protection after a single priming dose, support projections of eliminating vaccine-targeted types in populations with achievable coverage rates in adolescents, and offer insights for developing future antimicrobial vaccines.
Cite This Study
Schiller et al. (2026) studied this question.